Analysis association between mitochondrial genome instability and xenobiotic metabolizing genes in human breast cancer by Pavicic, Walter Hernán et al.
Analysis Association between Mitochondrial Genome 
Instability and Xenobiotic Metabolizing Genes in Human 
Breast Cancer
Walter H Pavide, Martin Laguens, and Silvina M Richard
IMBICE, Instituto Multidisciplinario de Biología Celular, La Plata, Argentina
The aim of this study was to determine the existence of association between the genetic polymorphisms of metabolizing genes 
GSTM-1, GSTT-1, and NAT-2, and the presence of mitochondrial genome instability (mtGI) in breast cancer cases. Ninety-four pairs 
of tumoral/nontumoral breast cancer samples were analyzed. Our samples showed 40.42% of mtGI by analysis of two D-loop re­
gion markers, a (CA)n mtMS starting at the 514-bp position, and four informative Mnl\ sites between the 16,108-16,420-bp. GSTM-1 null 
genotype has shown a significant association with mtGI presence (x2 = 7.62; P = 0.006) in breast cancer cases; moreover, these 
genotypes also are related to an increased risk for mtDNA damage (odds ratio (OR) =3.71 (1.41-9.88); 95% Cornfield confidence 
interval (Cl)). These results suggest that the absence of GSTM-1 enzymatic activity favors chemical actions in damaging the 
mtDNA. Analysis of GSTT-1 and NAT-2 polymorphisms showed no association with mtGI (x2 = 0.03; P = 0.87 and x2 = 2.76; P = 0.09, 
respectively). The analysis of invasive breast cancer cases showed mtGI in 74.36% of ILC cases (29 of 39 samples), and in only 
18.75% (9 out of 48) IDC cases; this result suggests a possible relation between mtDNA mutations and variations in molecular path­
ways of tumor development.




Worldwide, breast cancer is the fifth 
most common cause of cancer death and 
the first cause among women (1). Ap­
proximately 40% of breast cancer cases 
show nuclear genome instability (NGI), 
due to the malfunction of one or more 
genes forming the cohort of mismatch re­
pair genes (MMR) (2,3), while more than 
60% show mtGI, a second form of insta­
bility associated with tumors and charac­
terized by the presence of point muta­
tions or length tract instabilities in 
mtDNA (4,5).
The finding of mutations and deletions 
in mtDNA of tumor cells has focused the 
attention on these cytoplasmic organelles 
as concurrent factors in the start or 
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progress of tumors (6). However, little is 
known about the mtGI, their presence 
and frequency variation among tumors, 
the mechanisms involved in their origin, 
and their role in human cancers.
The human mtDNA is a 16,569-bp, cir­
cular and double-stranded molecule. All 
the mt genome encoded genes are orga­
nized continuously with noncoding in­
tervening sequences except for a small 
segment called displacement-loop 
(D-loop), which comprises some of the 
replication and transcription origins of 
the mt-genome (7).
Trying to clarify the origin of mtGI and 
their role in human cancers, particularly 
in breast cancer, our group previously 
showed that causes of the appearance of 
NGI are not involved in mtGI (8). This 
result was confirmed later by other work 
(9,10,11), allowing us to conclude that 
NGI and mtGI are independent events 
with different mechanisms of origin.
Moreover, in the last year, there was 
significant progress regarding the func­
tion of the metabolizing enzymes and 
their role in the elimination of a very 
wide class of DNA damage compounds 
(1). The xenobiotic metabolizing en­
zymes (XME) are a family of enzymes 
coded by the xenobiotic metabolizing 
genes (XMG). There are more than 
twelve different families of enzymes that 
have been described for almost all ge­
netic polymorphisms that modified their 
activity efficiency, and that are responsi­
ble for wide inter-individual variation in 
drug metabolism (12).
The human mammary gland is ex­
posed to agents capable of inflicting 
DNA damage and thereby initiating 
tumor induction (13,14,15). Most of these 
potential human mammary carcinogens 
require enzyme-catalyzed steps to effect 
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biotransformation to DNA-reactive 
metabolites. Although hepatic enzymes 
are likely to play a role in the metabo­
lism of potential breast carcinogens, it is 
important to consider that enzymes ex­
pressed locally in the target site also 
have relevant influence in modulating 
DNA-reactive species levels (1).
Glutathione S-Transferase isoforms, a 
(GSTM-1) and r (GSTT-1), and N-Acetyl 
Transferase 2 (NAT-2) are enzymes which 
demonstrate expression in mammary tis­
sues (1). For both the GST enzymes, the 
deficiency is due to a deletion of the en­
tire genomic coding region, giving rise 
to the allele known as "null." The dele­
tion in a homozygous state determines 
the polymorphism called "null geno­
type," with the consequent absence of 
total enzymatic activity. Regarding the 
NAT-2 gene, at least 19 variant alleles 
have been detected in the human popu­
lation (16), but the NAT-2*5, *6, and *7 
alleles account for virtually all of the 
slow acetylator alleles in the Caucasian 
population, providing evidence for a 
high concordance between genotype and 
phenotype (17).
In this report, we first analyze pairs of 
breast non tumoral/tumoral tissues for 
the presence of mtGI, studying two 
markers of the D-loop region which have 
a low spontaneous rate of mutation in 
germline cells, a (CA)n mt MS (micro­
satellite) starting at the 514-bp position, 
and four informative Mnll sites located 
between the 16,108-bp and 16,420-bp po­
sition (8). Second, we analyze the poly­
morphism of GSTM-1, GSTT-1, and 
NAT-2 in breast cancer patients with and 
without mtGI, trying to determine 
whether this instability is associated with 
a specific allele for the XMG. Further­
more, we analyzed the possible correla­
tion between the presence of mtGI and 




Ninety-four breast cancer samples and 
their adjacent nontumoral tissues were 
obtained from female patients at a Clini­
cal Center from La Plata City (Buenos 
Aires, Argentina), who underwent surgi­
cal resection between 1997 and 2004, ac­
cording to the Institutional Review Board 
approved protocol. We have selected 
only those patients who did not undergo 
pretreatments (radio- or chemotherapy) 
before surgery. A representative tissue 
section was stained with haematoxylin 
and eosin and semiquantitatively as­
sessed for tumor area percentage over 
the total sample area by one of the au­
thors (M Laguens); cancer regions se­
lected for DNA extraction showed >90% 
abnormal cells. Histological typing was 
based on standard criteria (18). All the 
donors gave informed consent for the 
study. The DNA extraction was per­
formed using a Qiagen DNeasy Blood & 
Tissue Kit (Qiagen, Valencia, CA, USA).
mtDNA Analysis
The (CA)h MS, starting at 514 bp and 
showing five haploid alleles differing in 
size by the number of dinucleotide re­
peats (7), was amplified with the primers 
and polymerase chain reaction (PCR) 
conditions reported by Szibor et al. (19). 
Microsatellite allele identification was 
performed by electrophoresis in 15% 
neutral polyacrylamide and Sybr-Green 
fluorescence.
Restriction fragment length poly­
morphisms (RFLP), for Mnll sites 
[CCTC(,(N)7] between nontumoral (Nt) 
and tumoral (T) tissue, were detected in 
an mtDNA fragment of 312 bp extending 
from the 16,108 bp position to the 16,420 
bp position (7). PCR conditions and 
primers were as reported previously in 
Richard et al. (8). According to the refer­
ence sequence of Anderson et al. (7), the 
312 bp fragment comprises five Mnll 
sites producing fragments of 118, 89, 39, 
35, 28, and 3 bp. With the exception of 
the 3 bp fragment, which could not be 
identified due to its small size, all of the 
other fragments and their corresponding 
RFLP patterns were detected by elec­
trophoresis in 10% neutral polyacry­
lamide visualized by Sybr-Green fluores­
cence staining.
Those pairs of tumoral and nontu­
moral samples showing mt markers 
heteroplasmy and/or changes between 
both tissues were tested 2 to 4 times 
in independent studies performed by 
two researchers to confirm the consis­
tency of mt marker identifications 
and to exclude possible sample 
cross-contamination.
Analysis of Xenoblotlc Metabolizing 
Genes
GSTM-1 genotype analysis was car­
ried out by a modification of the duplex 
PCR procedure described by Hou et al. 
(20), replacing the internal PCR-positive 
control reaction (NAT-2), by a segment 
of the syntenic gene GSTM-2 (211pb, ac­
cession number STS-RH65389). Primers 
for GSTM-2 were: Fw: 5'- TgA AgT CCT 
TCA ggT TTg gg -3'; Rw: 5'- CAg CCA 
Tgg TTT CTT CTT ggg -3', and the an­
nealing temperature was 58°C. This 
method allows us to identify individu­
als with one or two copies of the GSTM- 
1 allele (showed both the GSTM-1 and 
the control band), from individuals 
with a homozygous deletion (null 
genotype only amplifies the control 
gene). GSTT-1 genotype was deter­
mined using the same duplex PCR 
conditions and primers reported by 
Baranova et al. (21).
Identification of NAT-2 slow acetyla- 
tors was performed by PCR method and 
specific restriction endonucleases analy­
sis as reported previously in Hou et al. 
(20). The NAT-2 mutant alleles were 
identified by the substitution nucleo­
tides, and loss of a restriction site, in 
C481T (Kpnl), G590A (TaqI), and G857A 
(BamHT), allele *5, *6, and *7, respectively. 
The wild-type allele (NAT-2 *4) was de­
fined by the absence of such substitu­
tions. Correlation phenotype/genotype, 
the presence of at least one wild-type al­
lele, confers an intermediate acetylator 
phenotype (NAT2*I), whereas two mu­
tant alleles are required for the slow 
acetylator phenotype (NAT2*S). The 
wild-type allele in a homozygous state 
determines the rapid acetylator pheno­
type (NAT2*R) (20,22).
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Statistical Methods
The x2 test was used to study the dif­
ference in the genotype distributions. 
Relative risk was estimated with Odds 
Ratio (OR) and the Cornfield 95% confi­
dence interval (95% CI). P values (two- 
sided) below 0.05 or Odds Ratio with a 
95% CI over or below 1.0 were consid­
ered statistically significant.
RESULTS
mtDNA Analysis: (CA)n mtMSI and 
Mnl\ RFLPs In Nt/T Tissue
Over a total of 94 breast tissues ana­
lyzed for (CA)h MS, we detected eight 
heteroplasmic samples (8.51%). The analy­
sis of tumor sample counterparts showed 
allele changes in 24 of 94 cases (25.53%).
The appearance of Mull mutations was 
observed in 28 of 94 cases of breast can­
cer patients (29.79%), comparing the di­
gestion pattern in tumoral tissues with 
the nontumoral counterpart. Moreover, 
we observed that five of these samples 
showed heteroplasmy in the nontumoral 
tissue (presence of two different diges­
tion patterns).
We considered a case unstable when it 
had a changed allele in the mtMS, differ­
ence in the digestion pattern for MnlL, or 
both events in parallel; therefore, if we 
combine MS and Mull data, the mtGI ob­
served in cancer tissues was 38 of 94 
(40.42%).
Histopathological Types of Breast 
Cancer and mtGI Event Analysis 
Association
The possible correlation was evaluated 
in 94 total cases, consisting of one case of 
LCIS (Lobular Carcinoma In Situ), 39 
cases of ILC (Lobular Carcinoma Inva­
sive), six cases of DCIS (Ductal Carci­
noma In Situ), and 48 cases of IDC (Duc­
tal Carcinoma Invasive).
Forty-one samples from the 94 total 
cases analyzed showed mtGI, 29 showed 
ILC (70.73%), whereas only 9 cases 
showed IDC (21.95%), and the remaining 
3 cases showed DCIS (7.32%).
Analyzing particularly invasive case 
results, we found mtGI in 74.36% of the
Table 1. Genotype frequencies of xenobiotic metabolizing genes.
Gene and genotype
Frequency
ReferenceCases,13 n (%) Reported13
GSTM-1 94
null/null 38 (40.4) 42-60 (20,29,32,39)
+f+/null 56 (59.6) 40-58
GSTT-1 94
null/null 17(18) 16-21.5 (29,32)
+f+/null 77 (82) 78.5-84
NAT-2 94
Rapid 7(7.4) 52(553) 36.8-60.1 (20,40)
Intermediate 45(47.9) Ç ?
Slow 42 (44.7) 39.9-63.2
aFrequency found in nontumoral samples with n number of case studied for each gene. 
bAverage frequency and standard deviations estimated according to the data published 
by other groups (bibliographic reference), in normal subjects of similar ethnicity (since it 
works with the average, the sum of the averages of the two genotypes of a particular 
gene may be less than 100).
total ILC cases (29 of 39 samples) and in 
18.75% of the total IDC cases (9 of 48 
samples). The use of statistical analysis 
to compare this distribution revealed a 
significant association between the pres­
ence of the mtGI phenomenon and the 
ILC histophatological type of breast can­
cer (x2 = 24.83; P < 0.001; OR = 12.57 
[4.08-40.39]; 95% CI).
Analysis of Xenobiotic Metabolizing 
Genes
None of the obtained frequencies for 
the xenobiotic metabolizing gene poly­
morphisms studied showed significant 
differences with data reported for the 
same ethnic population (Table 1).
Of 35 mtGI tumors, 21 (60%) were ho­
mozygous for the GSTM-1 null allele. In 
contrast, 71.2% of the samples carrying 
the gene in hetero- or homozygosity (42 
of 59 cases) showed a stable mt genome 
(without detection of mutations or insta­
bility). Those opposite values of observed 
percentages indicate that the GSTM-1 
null genotype may be correlated with the 
presence of mtDNA instability. Evaluat­
ing this possibility with statistical meth­
ods, we observed that, effectively, there 
was a positive significant association (x2 = 
7.62; P = 0.006) for the events mentioned 
above (Table 2). Moreover, the OR value 
obtained (OR = 3.71 [1.41-9.88]; 95% CI), 
confirms the correlation between the ho­
mozygous deletion of the gene as a risk 
factor for mtGI generation.
The analysis for GSTT-1 gene showed 
that 32 of 94 samples analyzed showed 
mtGI, from which only five (15.6%) have 
the null genotype, whereas the remain­
ing 84.4% (27 of 32) carry one or two 
copies of the allele. Using a statistical 
method, we found no significant correla­
tion between mtGI and GSTT-1 homozy­
gous null (x2 = 0.03; P = 0.87), as shown 
in Table 2.
Analyzing a total of 94 cases for three 
NAT-2 gene polymorphisms (C481T, 
G590A, and G857A), we found that 
seven cases were rapid acetylator (7.4%), 
45 were intermediate acetylator (47.9%), 
and 42 were slow acetylators (44.7%) 
(Table 1). To analyze the possible correla­
tion between the acetylator type for 
NAT-2 and the presence of mtGI, we con­
sidered the intermediate and rapid acety­
lator together because of the small num­
ber of the latter. The statistical methods, 
evaluating the *S versus *I/*R acetyla­
tors, showed that there is no significant 
association (x2 = 2.76; P = 0.09) (Table 2). 
We also assessed, separately, the correla­
tion between mtGI and each of the acety­
lators studied (*R, *1, and *S), and we 
found no significant association (statisti­
cal data not shown).
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Table 2. Genotype analysis association with mtGI and metabolizing genes.
mtGI
Gene and Absence, Presence, Odds ratio P
Genotype n(%) n(%) (95% Cl) value
GSTM-1 59 35
+a 42 (71.2) 14 (40) 1 (reference)
null 17 (28.8) 21 (60) 3.71 (1.41-9.88) 0.006b
GSTT-1 62 32
+ 50 (80.6) 27 (84.4) 1 (reference)
null 12 (19.4) 5(15.6) 0.77 (0.21-2.71) 0.87c
NAT-2 62 32
R.(l 30 (48.4) 22 (68.8) 1 (reference)
S 32 (51.6) 10(31.2) 0.43 (0.16-1.14) 0.09d
aCases carrying the GSTM-1 gene in hetero- or homozygosis.
bGSTM-l null versus "¿-"genotype, the first had a significant overrepresentation of cases 
with mtGI.
CGSTT-1 null versus"+" genotype, nonsignificant difference.
dNAT-2 slow versus rapid/intermediate acetylators, nonsignificant difference.
DISCUSSION
Mitochondrial Genome Instability
It is believed that mutations in the mi­
tochondrial genome contribute to the 
process of carcinogenesis. In recent years 
the existence of alterations in the mtDNA 
in several human cancers (gastric, colo­
rectal, lung, and breast) has been demon­
strated (23).
We found that 38 of 94 cases (40.42%) 
showed mtGI when both markers from 
the D-Loop region were analyzed. Our 
group published one of the first works to 
evaluate the existence of mtGI in breast 
cancer (24), finding mutations in the en­
tire mt genome of tumoral cells (5 of 7 
cases), but not in nontumoral cells. Sub­
sequently, other works also describe the 
presence of mutations at the mtDNA 
when compared with the mammary tu­
moral sample and paired with adjacent 
nontumoral tissues from the same pa­
tient. Sequencing the entire mt genome, 
Zhu et al. (25) identified one or more so­
matic mutations in 14 of 15 (93%) breast 
cancer cases studied; while Tan et al. (26) 
found that 74% (14 of 19 tumors ana­
lyzed) displayed at least one somatic 
mtDNA mutation, and that 81% of the 
changes were in the D-loop region (22 of 
27 different somatic mutations). Richard 
et al. (8), analyzing the D-Loop region in 
40 pairs of breast Nt/T tissues, observed 
a 65% mtGI in cancer tissues; while on 
the other hand, Alazzouzi et al.(9) found 
10.8% (4 of 34) of mtGI in ductal breast 
cancer cases.
The high frequency of somatic muta­
tion reported for the mtDNA in breast 
cancer cases and the percentage of mtGI 
found in our series (40.42%) show that 
this instability is not a sporadic phenom­
enon, but rather is a detectable feature in 
a high rate of breast cancer cases studied, 
as well as for other carcinomas (lung, 
gastric, and colorectal cancers) (27). De­
spite this, testicular tumors did not show 
mtGI (0 of 17 cases) (4), neither did blad­
der tumors (in a preliminary analysis we 
found that 0 of 10 cases studied showed 
this event). Consequently, this data could 
reflect the existence and/or succession of 
certain conditions that favor the mtGI 
generation in some tumors but not in oth­
ers. One explanation would be the pres­
ence of a barrier mechanism acting only 
in a particular tissue and preventing the 
induction of mutations locally; for exam­
ple, specific metabolizing enzyme(s) (1), 
as we will discuss later for the XMG 
studied in the present report.
mtGI and Breast Cancer 
Histopathological Type
Presently, we have found that 74.36% 
of ILC samples presented the mtGI phe­
nomenon (29 of 39 samples), while only 
18.75% of total IDC samples showed this 
event (9 of 48 cases). A low percentage of 
mtGI for IDC (10.8%) was reported pre­
viously by Alazzouzi et al. (9).
The possible correlation between mtGI 
frequencies and the histopathological 
features of the samples was evaluated 
previously by other researchers, both for 
breast cancer and other types of tumors. 
In malignant melanomas, the mtMSI in­
cidence increased from 3% (one case) of 
sporadic malignant melanomas (SSM), to 
13% (four cases) of nodular melanoma 
(NM), and even more in metastatic 
melanomas (MM) with 20% (nine cases). 
The mtMSI was determined analyzing 
insertions and/or deletions at the D-310 
homopolymer C tract and the MS (CA)n 
(nt514-nt523) (28). Although only 4 of 37 
(10.8%) ductal type breast cancer cases 
analyzed by Alazzouzi et al. (9) showed 
mtGI, 3 of the 4 cases corresponded to 
grade III tumors.
These data suggest that mtGI could be 
related to variations in molecular path­
ways of tumor development in breast 
cancer subtypes. Our results show this 
as well, with a higher percentage of 
cases with mtGI in ILC than in IDC 
breast cancer.
Analysis Association between mtGI 
and the XMG Studied
GSTM-1. We found a higher signifi­
cant association (y2 = 7.62; P = 0.006), be­
tween the null genotype and the pres­
ence of mtGI (OR = 3.71 [1.41-9.88]; 95% 
CI) (Table 2).
The finding of GSTM-1 null genotype as 
a susceptibility factor risk for breast cancer 
has been reported previously (29,30,31). 
Helzlsouer et al. (32) reported an increased 
breast cancer risk in women with the null 
genotype (OR = 2.10 [1.22-3.64]; 95% CI). 
Charrier et al. (33) found a positive associ­
ation in postmenopausal women, while 
Ambrosone et al. (34) found a correlation 
between GSTM-1 null and younger post­
menopausal women with breast cancer. 
Moreover, Rebbeck et al. (35) examined 
breast cancer patients with a family his­
tory and found no association between 
GSTM-1 null allele and tumor risk.
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However, we can point out that so far 
no study has analyzed its possible associ­
ation with mtGI event, as is done in the 
present report.
It is known that the GSTM-1 isoform 
(mu, ri) is expressed in human breast tis­
sue cells (1,36). Moreover, a study con­
ducted in mouse liver mitochondria 
demonstrates that its concentration is in­
duced by the presence of toxic metabo­
lites (as in oxidative stress conditions) in 
the mitochondrial matrix, as well as in 
the cytosolic compartment (37,38). These 
enzyme properties, along with the fact 
that human breast tissues are exposed to 
a large number of genotoxic compounds 
(most of which are metabolized by 
GSTM-1 enzyme [1], including products 
such as reactive oxygen species [ROS] 
[37]), support our correlation result be­
tween GSTM-1 null genotype and an in­
crease in mtGI. Gene deletion in only one 
allele also causes enzyme activity to de­
crease, so we could assume that this 
deletion also could be involved in mtGI 
generation.
Although in the present report we men­
tioned that GSTM-1 null genotype could 
be a risk factor for mtGI presence, it also 
is possible that GSTM-1 "+" acts as a pro­
tective factor for mtDNA damage. The 
GSTM-1 genotype distribution in cases 
with mtGI presence is closer to numbers 
reported previously; whereas GSTM-1 fre­
quencies in those with mtGI absence are 
different from the accepted limit percent­
ages in the literature (Tables 1,2). There­
fore we should consider the possibility of 
a protective role of the enzyme encoded 
by GSTM-1 gene rather than the null 
genotype as a risk factor for mitochondr­
ial genome damage.
Figure 1 shows a hypothetical diagram 
about the processes that occur within the 
mitochondrial matrix in reference to the 
damage caused by reactive compounds 
in the presence or absence of the GSTM-1 
enzyme.
GSTT-1 and NAT-2. Our results have 
shown that neither the GSTT-1 null geno­
type (P = 0.87) nor the different acetyla- 
tors for NAT-2 (P = 0.09) have significant 





'■GSH' Free Glutathion in 
solution (non conjugated).
Figure 1. Here we diagram the possible role GSTM-1 enzyme plays inside the mitochondrial 
matrix as mtDNA protector factor regarding damage caused by reactive species. The bio­
logical systems can produce these compounds by different pathways. One of the most im­
portant endogenous mechanisms is the respiratory chain, generating great levels of ROS 
during the O2 reduction. Lipid peroxidation over the membrane lipoprotein, caused by ROS 
action, is another source of active compounds (HNE: 4-Hydroxynonenal, for example). An­
other important mechanism involved in ROS generation is the biotransformation of different 
exogenous compounds or xenobiotics by action of different XME. The ROS action into the 
cell could produce lesions in different mt compounds, such as lipids; damage different kinds 
of proteins, Poky for example; damage the mtDNA directly by action of these active 
species on the bases, or indirectly by DNA replication with a faulty Poky that introduces er­
rors. Altogether, those deleterious processes lead to genotoxic damage, as shown in the 
right side of the image. The left side shows the possible metabolic pathway of the GSTM-1 
enzyme, promoting the elimination of reactive species and blocking their deleterious effect 
over the mt component. It is important to note the possible protective action of GSTM-1 
over the mtDNA. The picture shows only a schematic pathway for the GSTM-1 enzyme; the 
other mitochondrial matrix events are simplified.
breast cancer samples (Table 2). A possi­
ble explanation is that, although expres­
sion of these genes was detected in the 
mammary tissue, the encoded enzymes 
do not show enzymatic activity inside 
the mitochondrial matrix (1). This allows
-< GS£) Conjugated Glutathion, by GSTM-1 action, with: ÇLPÇÏXGSS) Lipoperoxides;
(ROS GS i Reactive Oxygen Species; jÂÏGS~) other xen°biotic
- ------ or reactive compounds.
us to conclude that the action of damag­
ing metabolites on the mt genome is not 
mediated and/or regulated by these en­
zymes on a local level. So, the presence 
of mtGI in breast cancer tissues was in­
dependent of those XMG.
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CONCLUSION
As we point out above, the action of 
GSTM-1 as a barrier defense could pre­
vent the induction and accumulation of 
mutations at an mtDNA level in breast 
tissue. Consequently, a locally metaboliz­
ing enzyme activity could have an effec­
tive and important influence in modulat­
ing reactive species levels (Figure 1); this 
tissue-specific enzymatic activity inter­
variation could be an explanation for 
mtGI frequency differences reported for 
each type of tumor, as mentioned previ­
ously in the discussion.
Finally, it would be of great interest to 
generate a work line to study the role of 
protection and/or repair for different 
metabolizing enzymes in relation to the 
mtDNA damage generation. It also 
would be of interest to study whether 
the mtGI/GSTM-1 null correlation also is 
present in other tumor types in which 
the mtGI event was found, or if it is pres­
ent only in breast cancer tissues. New 
findings will enable us to have a better 
understanding about the mechanism of 
interrelationships which converge in the 
event of genomic damage, as well as for 
the carcinogenic process itself.
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